{"filing":{"accession_number":"0001395064-26-000329","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-05","primary_document":"form6k_080526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000329/form6k_080526.htm"},"events":[{"id":25722,"run_id":23343,"accession_number":"0001395064-26-000329","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The 6-K discloses FDA approval of ORZEYFUL (oveporexton), Takeda's first-in-class orexin receptor 2 agonist for narcolepsy type 1. This is a material regulatory milestone and product approval event that would affect investor assessment of the company's pipeline and commercial prospects. While not fitting the specific categories of earnings release, M\u0026A, or executive changes, it represents a significant operational and strategic achievement—the successful regulatory clearance of a novel therapeutic asset. The company notes this is \"just the beginning\" of its orexin franchise strategy, underscoring the strategic importance of this approval to the business.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":26625,"accession_number":"0001395064-26-000329","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The 6-K discloses FDA approval of ORZEYFUL (oveporexton), Takeda's first-in-class orexin receptor 2 agonist for narcolepsy type 1. This is a material regulatory milestone and product approval event that would affect investor assessment of the company's pipeline and commercial prospects. While not fitting the specific categories of earnings release, M\u0026A, or executive changes, it represents a significant operational and strategic achievement—the successful regulatory clearance of a novel therapeutic asset. The company notes this is \"just the beginning\" of its orexin franchise strategy, underscoring the strategic importance of this approval to the business.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:25:32.420289+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-08-06"}]}